Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

Minczeles, Noémie S; Bos, Eelke M.; Leeuw, Reinoud C. de; Kros, Johan M.; Konijnenberg, Mark; Bromberg, Jacoline E C; Herder, Wouter W. de; Dirven, Clemens; Hofland, Johannes; Brabander, Tessa

doi:10.1007/s00259-022-06044-9

Cited by 16 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies confirmed the poor outcome for high grade meningiomas treated with RLT [68,71]. Conversely, Minczeles et al [72] documented both a decline in tumor growth rate and a relatively good disease control in 15 patients who received [ 177 Lu]Lu-DOTATATE, with low systemic toxicity. Probably, baseline SSTR2 expression may play a key role in the correct selection of patients with aggressive meningiomas to address to RLT.…”

Section: Meningiomas Cup-nets and Other Rare Tumors Overexpressing Sstrmentioning

confidence: 94%

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

et al. 2023

View full text Add to dashboard Cite

Lutathera® is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive gastroenteropancreatic (GEP) neuroendocrine neoplasms (NET) can be treated with Lutathera®. Conversely, patients with SSTR-positive disease arising from outside the gastroenteric region do not currently have access to Lutathera® treatment despite several papers in the literature reporting the effectiveness and safety of RLT in these settings. Moreover, patients with well-differentiated G3 GEP-NET are also still “Lutathera orphans”, and retreatment with RLT in patients with disease relapse is currently not approved. The aim of this critical review is to summarize current literature evidence assessing the role of Lutathera® outside the approved indications. Moreover, ongoing clinical trials evaluating new possible applications of Lutathera® will be considered and discussed to provide an updated picture of future investigations.

show abstract

Section: Meningiomas Cup-nets and Other Rare Tumors Overexpressing Sstrmentioning

confidence: 94%

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The TGR decreased to 3.1% in surface (P=0.016) and 5.0% in volume (P=0.013) per month after treatment. The results suggest that 177 Lu-DOTA-TATE can control tumor growth ( 52 ).…”

Section: Clinical Application Of 177 Lu In Other D...mentioning

confidence: 99%

Current clinical application of lutetium‑177 in solid tumors (Review)

Niu,

Fan,

Lin

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Radionuclide-based therapy represents a novel treatment regimen for tumors. Among these therapies, lutetium-177 ( 177 Lu) has gained significant attention due to its stability and safety, as well as its ability to emit both γ and β rays, allowing for both imaging with single photon emission computed tomography and tumor treatment. As a result, 177 Lu can be used for both diagnosis and treatment for diseases such as prostatic and gastric cancer. Therefore, based on the available data, the present review provides a brief overview of the clinical applications of 177 Lu-targeted radionuclide therapy in metastatic prostate cancer, neuroendocrine tumors and other types of solid tumors, and highlights the current therapeutic effect, reduction in damage to normal tissues and future research directions, including the development of new nuclides and the application of more nuclides in different tumors. In the future, such treatments could be used in more tumors.

show abstract

“…Treatment options encompass mainly neurosurgical resection and external-beam irradiation. PRRT is currently considered in meningiomas that cannot be treated by surgery or conventional radiation therapy regardless of their grade (27,28). PRRT targets somatostatin receptor (SSTR) type 2, since meningiomas almost invariably express SSTR type 2 (29) which can be monitored with SSTR-targeted PET imaging.…”

Section: Meningiomas Contextmentioning

confidence: 99%

Theranostics in Neurooncology: Heading Toward New Horizons

Tolboom,

Verger,

Albert

et al. 2023

J Nucl Med

View full text Add to dashboard Cite

Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

Cited by 16 publications

References 40 publications

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

Current clinical application of lutetium‑177 in solid tumors (Review)

Theranostics in Neurooncology: Heading Toward New Horizons

Contact Info

Product

Resources

About